Podcast

Bringing Together the Lung Cancer Community

Author(s):

Kristie L. Kahl

In this episode of the “CURE Talks Cancer” podcast, we looked back on CURE’s Lung Cancer Heroes event and recognized each winner that helps bring together the lung cancer community to raise awareness.

On October 15th, CURE® recognized five individuals for their contributions to the lung cancer space and raising awareness to end the stigma, inform, connect, and empower anyone who has been impacted by lung cancer.

During the inaugural virtual event, four individuals — two physicians, a nurse and a patient turned advocate — were awarded for their contributions to the lung cancer community. The program also recognized one Lifetime Achievement award winner.

lung cancer, Takeda, heroes, patients, community

In this episode of the “CURE Talks Cancer” podcast, we spoke with Bonnie J. Addario, Carolyn Baggett, Dr. Jennifer Garst, Dr. Fred Hirsh and Deborah Pickworth about their contributions and why bringing the lung cancer community is vital in raising awareness around the disease.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of Dr. Reznick
There are a number of reasons why patients with cancer are encouraged to enroll in clinical trials, Dr. Michael J. Pishvaian explained.
a man and a woman in front of a dark blue background for CURE Speaking Out
a man and a woman in front of a dark blue background for CURE Speaking Out
a man and a woman in front of a dark blue background for CURE Speaking Out
a man and a woman in front of a dark blue background for CURE Speaking Out
Image of a man in a suit.
Image of man with black hair.
Related Content
Optune Lua received a CE Mark for metastatic non–small cell lung cancer with immune checkpoint inhibitors or docetaxel.
April 23rd 2025

Optune Lua Receives CE Mark in Europe for Metastatic NSCLC

Alex Biese
Optune Lua received a CE Mark for metastatic non–small cell lung cancer with immune checkpoint inhibitors or docetaxel.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
On January 15, people gathered for the Air Matters: Radon & The Environment Community Education Event.
April 22nd 2025

Air Matters: Radon and the Environment

Lung Cancer Initiative (LCI)
cancer horizons podcast logo: a white microphone on a blue background
March 4th 2024

Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

Alex Biese Brielle Benyon
In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
Image of Lungs.
April 18th 2025

First Patient Dosed in a Phase 1/2 Trial for Small Cell Lung Cancer

Ryan Scott
The first patient with small cell lung cancer has been dosed in a phase 1/2 trial investigating first-line iadademstat plus immune checkpoint inhibitors.
Deferring upfront CNS-directed radiation in EGFR-variant and ALK-positive NSCLC may improve outcomes but raises treatment-related toxicity risks: © stock.adobe.com
April 18th 2025

Radiation Delay in NSCLC May Aid Outcomes, But Raises Toxicity Risks

Alex Biese
Deferring upfront CNS-directed radiation in EGFR-variant and ALK-positive NSCLC may improve outcomes but raises treatment-related toxicity risks.